Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD safety, tolerability, and pharmacokinetics in adults with kidney failure and chronic symptoms
ACTRN12622000383763Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cannabidiol in chronic kidney disease (CKD) and kidney failure, sponsored by University of Sydney. Primary endpoints: Safety and Tolerability. Started Mar 2023; status: completed.
02
Drugs
cannabidiol
03
Conditions
chronic kidney disease (CKD)kidney failure
Beyond the preview
Go deeper on ACTRN12622000383763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000383763.